3-acetyl-11-keto-β-Boswellic Acid
(Synonyms: 11-羰基-Β-乙酰乳香酸,3-O-acetyl-11-keto-β-Boswellic acid,AKBA) 目录号 : GC14282A selective 5-LO inhibitor
Cas No.:67416-61-9
Sample solution is provided at 25 µL, 10mM.
IC50: 1.5 μM
3-acetyl-11-keto-β-Boswellic Acid, as known as AKBA, is a pentacyclic triterpene that suppresses 5-lipoxygenase in a selective, nonredox, enzyme-directed, and noncompetitive manner. Also, AKBA inhibits topoisomeraseⅠ and NF-κB signaling. AKBA has been studied for potential use in the control of inflammatory diseases, including arthritis and cancer.
In vitro: AKBA exerted a time- and concentration -dependent cytotoxicity on androgen-independent prostate cancer cells. AKBA blocked proliferation and elicited apoptosis in the chemoresistant and androgen-independent human PC-3 prostate cancer cells by the release of mitochondrial cytochrome c and DNA fragmentation. Also, AKBA concentration-dependently inhibited NF-κB signaling, yet it did not directly affect the NF-κB binding to DNA. Additionally, AKBA suppressed inhibitor κB kinase and NF-κB-dependent antiapoptotic gene products in PC-3 cells [1].
In vivo: PC-3 xenotransplanted male NMRI/nu-nu mice were injected intraperitoneally at 100 μmol/kg daily for three weeks. AKBA dampened growth and proliferation of PC-3 xenografts in nude mice and elicited apoptosis. Moreover, compared with the control group, AKBA reduced the tumor volume and the invasiveness of the tumor into the surrounding tissues [1].
Reference:
[1]. Syrovets, T., Gschwend, J., Buchele, B., Laumonnier, Y., Zugmaier, W., Genze, F., & Simmet, T. Inhibition of IκB Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo. Journal of Biological Chemistry. 2004; 280(7): 6170-6180.
Cas No. | 67416-61-9 | SDF | |
别名 | 11-羰基-Β-乙酰乳香酸,3-O-acetyl-11-keto-β-Boswellic acid,AKBA | ||
化学名 | (3α,4β)-3-(acetyloxy)-11-oxo-urs-12-en-23-oic acid | ||
Canonical SMILES | O=C1C=C2[C@](CC[C@]3(C)[C@@]2([H])[C@@H](C)[C@H](C)CC3)(C)[C@]4(C)CC[C@@]5([H])[C@@](C)(C(O)=O)[C@H](OC(C)=O)CC[C@]5(C)[C@]41[H] | ||
分子式 | C32H48O5 | 分子量 | 512.7 |
溶解度 | ≤5mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9505 mL | 9.7523 mL | 19.5046 mL |
5 mM | 0.3901 mL | 1.9505 mL | 3.9009 mL |
10 mM | 0.195 mL | 0.9752 mL | 1.9505 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet